IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10000511 B1

PDFFull Text
Date of Patent:
Jun. 19, 2018

Filed:

May. 06, 2015

Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders

Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Loren D. Walensky, Newton Centre, MA (US);

Michelle L. Stewart, Brookline, MA (US);

Nicole Cohen, Newton, MA (US);

Assignee:

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Yih-Horng Shiao

Int. Cl.
CPC ...
C07D 513/04 (2006.01); C07D 249/12 (2006.01); C07D 401/12 (2006.01); C07D 413/14 (2006.01); C07D 409/12 (2006.01); C07C 311/20 (2006.01); C07D 409/14 (2006.01); C07D 405/14 (2006.01); C07D 417/14 (2006.01); C07D 307/54 (2006.01); C07D 405/12 (2006.01); C07D 409/06 (2006.01); C07D 413/06 (2006.01); C07D 279/06 (2006.01); C07D 327/04 (2006.01); C07D 239/60 (2006.01); C07D 403/06 (2006.01); C07D 277/34 (2006.01); C07D 417/04 (2006.01); C07C 337/08 (2006.01); C07C 251/20 (2006.01); C07C 251/84 (2006.01); C07C 335/16 (2006.01); C07D 403/04 (2006.01); C07D 403/08 (2006.01);
U.S. Cl.
CPC ...
C07D 513/04 (2013.01); C07C 251/20 (2013.01); C07C 251/84 (2013.01); C07C 311/20 (2013.01); C07C 335/16 (2013.01); C07C 337/08 (2013.01); C07D 239/60 (2013.01); C07D 249/12 (2013.01); C07D 277/34 (2013.01); C07D 279/06 (2013.01); C07D 307/54 (2013.01); C07D 327/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/08 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/06 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/06 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07C 2602/10 (2017.05);
Abstract

This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.

Find Patent Forward Citations

Loading…